Results 131 to 140 of about 214,937 (381)

Cytomegalovirus gastritis

open access: yesWorld Journal of Gastrointestinal Endoscopy, 2010
Cytomegalovirus (CMV) has been increasingly recognized as an important common pathogen in an immunocompromised state. The colon and stomach are the most common sites of its gastrointestinal infection. Symptoms of CMV gastritis are usually nonspecific and include epigastric pain, fever, nausea and bleeding.
Akira, Hokama   +6 more
openaire   +2 more sources

Severe Gastritis after Administration of Nivolumab and Ipilimumab

open access: yesCase Reports in Oncology, 2018
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies.
Yoshito Nishimura   +6 more
semanticscholar   +1 more source

The proteomic differences and expression of fatty acid‐binding protein 6 (FABP6) associated with gastrointestinal injury in horses with oral administration of a clinical dose of phenylbutazone

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Phenylbutazone (PBZ) can potentially induce gastrointestinal ulceration, and early detection of PBZ‐induced gastroenteropathy will be useful for the diagnosis, treatment, and prevention of PBZ toxicity. Objectives To identify putative proteins associated with equine gastric ulcer syndrome after clinical dose (4.4 mg/kg ...
Ruethaiwan Vinijkumthorn   +6 more
wiley   +1 more source

The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus

open access: yesHistopathology, EarlyView.
The new OLGIMA method for histological gastric cancer risk assessment is based on the severity of glandular atrophy and intestinal metaplasia, in both antrum and corpus, according to the Updated Sydney classification. The highest score of either atrophy or intestinal metaplasia from each location will be used for the final OLGIMA stage.
Pedro Genaro Delgado Guillena   +125 more
wiley   +1 more source

Emphysematous Gastritis [PDF]

open access: yesJournal of Osteopathic Medicine, 2019
Afsana, Asharaf   +2 more
openaire   +2 more sources

Immune cell infiltration correlates with intestinal permeability, inflammation, and gastrointestinal symptoms in type 1 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
In individuals with type 1 diabetes, immune cell infiltration in the colon mucosa tended to correlate with fecal and systemic markers of intestinal permeability and inflammation, as well as gastrointestinal symptoms. These findings suggest that low‐grade gut immune activation might link the intestinal barrier dysfunction with systemic endotoxin ...
Polina Zalizko   +13 more
wiley   +1 more source

Prevalence and Risk Factors Associated with Gastritis in Patients Visiting Royal Prima Hospital

open access: yesProfessional Health Journal
Introduction:  Gastritis is an inflammation of the stomach lining caused by Helicobacter pylori and can be acute or chronic. This bacteria colonizes the stomach of more than 50% of humans and causes disease.
Zulkifli Adnan   +2 more
doaj   +1 more source

PENGARUH TERAPI BEKAM TERHADAP GEJALA GASTRITIS PADA MAHASISWA S1 KEPERAWATAN SEMESTER 8 DI UNIVERSITAS NAHDLATUL ULAMA SURABAYA [PDF]

open access: yes, 2017
Gastritis yang dialami mahasiswa akan sangat meganggu kegiatan perkuliahan mahasiswa, konsentrasi mahasiswa akan menurun karena rasa tidak nyaman pada bagian perut. Dan meskipun sudah di obati penyakit gastritis tidak dapat disembuhkan sepenuhnya. Tujuan
SARI, ERISKA YUNITA
core   +1 more source

Characterization of Gastric Tissue-Resident T Cells in Autoimmune and Helicobacter pylori-Associated Gastritis [PDF]

open access: gold, 2022
Daisuke Kametaka   +11 more
openalex   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy